Cat. #153166
Anti-Y hapten (C14) [NCRC55]
Cat. #: 153166
Sub-type: Primary antibody
Unit size: 100 ug
Availability: 3-4 weeks
Target: Y hapten
Class: Monoclonal
Application: FACS ; RIA
Reactivity: Human
Host: Mouse
£300.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: David Baldwin
Institute: University of Nottingham
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: Anti-Y hapten (C14) [NCRC55]
- Alternate name: C14
- Research fields: Cancer;Immunology
- Clone: NCRC55
- Tool sub type: Primary antibody
- Class: Monoclonal
- Conjugation: Unconjugated
- Strain: Balb/c
- Reactivity: Human
- Host: Mouse
- Application: FACS ; RIA
- Description: Y haptens are carbohydrate surface antigens formed by the difucosylation of Type-2-blood-group chains. The expression of Y haptens is frequently elevated in colo-rectal tumours in comparison to adjacent, apparently normal tissue.
- Isotype: IgG3
- Myeloma used: NS0
- Recommended controls: Human colonic adenoma
Target Details
- Target: Y hapten
- Tissue cell line specificity: Human colonic adenoma
- Target background: Y haptens are carbohydrate surface antigens formed by the difucosylation of Type-2-blood-group chains. The expression of Y haptens is frequently elevated in colo-rectal tumours in comparison to adjacent, apparently normal tissue.
Applications
- Application: FACS ; RIA
Handling
- Format: Liquid
- Unit size: 100 ug
- Storage buffer: PBS with 0.02% azide
- Storage conditions: -80° C
- Shipping conditions: Dry ice
References
- Price et al. 1986. Cancer Lett. 33(1):83-9. PMID: 3768863.
- Association of the Y hapten with glycoproteins, glycolipids and carcinoembryonic antigen in colorectal carcinoma.
- Brown et al. 1983. Biosci Rep. 3(2):163-70. PMID: 6189529.
- A monoclonal antibody against human colonic adenoma recognizes difucosylated Type-2-blood-group chains.
